![An Bang Lu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
An Bang Lu
Amministratore Delegato presso VISEN Pharmaceuticals
Posizioni attive di An Bang Lu
Società | Posizione | Inizio | Fine |
---|---|---|---|
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Direttore/Membro del Consiglio | 07/11/2018 | - |
Amministratore Delegato | 07/11/2018 | - | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - |
Storia della carriera di An Bang Lu
Precedenti posizioni note di An Bang Lu
Società | Posizione | Inizio | Fine |
---|---|---|---|
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Direttore/Membro del Consiglio | - | 01/06/2021 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Presidente | 01/01/2010 | 01/01/2014 |
Formazione di An Bang Lu
Taipei Medical University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Cina | 3 |
Giappone | 2 |
Taiwan | 2 |
Posizioni
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
Aziende private | 2 |
---|---|
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
- Borsa valori
- Insiders
- An Bang Lu
- Esperienza